CAR-T therapyAllo-HSCT within 1 yAuto-HSCT within 6 moAcute lymphocytic leukemiaAML/MDS with venetoclaxLymphoma on therapy within 1 yAnti-CD20/52 medication within 1 yGVHD on immunocompromising medication within 6 moReceipt of ATG within 1 yMultiple myeloma if anti-CD38/anti-BCMA within 1 yAplastic anemia. This evidence concerns the gene TNFRSF17 and anemia (phenotype).